

**FZD7 Antibody (Center)**  
**Affinity Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP18021c****Specification**

---

**FZD7 Antibody (Center) - Product Information**

Application	WB,E
Primary Accession	<a href="#">O75084</a>
Other Accession	<a href="#">O61090</a> , <a href="#">O57329</a> , <a href="#">NP_003498.1</a>
Reactivity	Human
Predicted	Chicken, Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	202-229

**FZD7 Antibody (Center) - Additional Information****Gene ID** 8324**Other Names**

Frizzled-7, Fz-7, hFz7, FzE3, FZD7

**Target/Specificity**

This FZD7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 202-229 amino acids from the Central region of human FZD7.

**Dilution**

WB~~1:1000

E~~Use at an assay dependent concentration.

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

FZD7 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

**FZD7 Antibody (Center) - Protein Information****Name** FZD7**Function** Receptor for Wnt proteins. Most frizzled receptors are coupled to the beta-catenin

canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. Activation by WNT8 induces expression of beta-catenin target genes (By similarity). Following ligand activation, binds to CCDC88C/DAPLE which displaces DVL1 from FZD7 and leads to inhibition of canonical Wnt signaling, activation of G-proteins by CCDC88C and triggering of non-canonical Wnt responses (PubMed:[26126266](#)). May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues.

#### Cellular Location

Cell membrane; Multi-pass membrane protein. Endosome membrane; Multi-pass membrane protein. Note=Associated to the plasma membrane in the presence of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2). Localized in recycling endosomes in other conditions

#### Tissue Location


High expression in adult skeletal muscle and fetal kidney, followed by fetal lung, adult heart, brain, and placenta Specifically expressed in squamous cell esophageal carcinomas

### FZD7 Antibody (Center) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### FZD7 Antibody (Center) - Images



FZD7 Antibody (Center) (Cat. #AP18021c) western blot analysis in K562 cell line lysates (35ug/lane). This demonstrates the FZD7 antibody detected the FZD7 protein (arrow).

### FZD7 Antibody (Center) - Background

Members of the 'frizzled' gene family encode 7-transmembrane domain proteins that are receptors for Wnt signaling proteins. The FZD7 protein contains an N-terminal signal sequence, 10 cysteine residues typical of the cysteine-rich extracellular domain of Fz family members, 7 putative transmembrane domains, and an intracellular C-terminal tail with a PDZ domain-binding motif. FZD7 gene expression may downregulate APC function and enhance beta-catenin-mediated signals in poorly differentiated human esophageal carcinomas.

#### **FZD7 Antibody (Center) - References**

Guey, L.T., et al. Eur. Urol. 57(2):283-292(2010)  
Vincan, E., et al. Dev. Dyn. 239(1):311-317(2010)  
Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :  
Hosgood, H.D. III, et al. Respir Med 103(12):1866-1870(2009)  
Ueno, K., et al. Br. J. Cancer 101(8):1374-1381(2009)